39 results
8-K
EX-99.1
RVMD
Revolution Medicines Inc
8 May 24
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
4:05pm
was due to the termination of the company’s collaboration agreement with Sanofi in 2023.
R&D Expenses: Research and development expenses were $118.0 … Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline
8-K
EX-99.1
RVMD
Revolution Medicines Inc
26 Feb 24
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
4:04pm
with Sanofi in 2023.
R&D Expenses: Research and development expenses were $148.5 million for the quarter ended December 31, 2023, compared to $66.1 million … .
R&D Expenses: Research and development expenses were $423.1 million for the year ended December 31, 2022, compared to $253.1 million for the year
8-K
EX-99.1
RVMD
Revolution Medicines Inc
6 Nov 23
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
4:05pm
ended September 30, 2023, compared to $3.4 million for the quarter ended September 30, 2022.
R&D Expenses: Research and development expenses were … . The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use
DEFA14A
RVMD
Revolution Medicines Inc
1 Nov 23
Additional proxy soliciting materials
7:15am
. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors
425
umzv32x gsp0
1 Nov 23
Business combination disclosure
7:11am
8-K
EX-99.1
7lb6xa ntb37
1 Nov 23
Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
7:08am
425
bqskve6 ur1m7furc3gh
23 Oct 23
Business combination disclosure
6:13am
DEFM14A
s17njhe
29 Sep 23
Proxy related to merger
4:19pm
424B3
in32cfm
29 Sep 23
Prospectus supplement
4:17pm
S-4/A
4wwwno3d4jupgye6
27 Sep 23
Registration of securities issued in business combination transactions (amended)
5:25pm
S-4
gl5llh
13 Sep 23
Registration of securities issued in business combination transactions
5:20pm
8-K
EX-99.1
d588t09a48eaqu3auhlf
8 Aug 23
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
4:04pm
425
hf5fyq5ung47iq4
1 Aug 23
Business combination disclosure
5:24pm
425
so20gnc4tvv6
1 Aug 23
Business combination disclosure
5:22pm
425
hwhq0e
1 Aug 23
Business combination disclosure
5:09pm
425
02pnmqpz u6pt
1 Aug 23
Business combination disclosure
7:15am
8-K
EX-99.2
k4ukytk9
1 Aug 23
Form of Parent Stockholder Voting Agreement
7:10am
8-K
EX-99.1
njy4jzb mw
8 May 23
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
4:04pm